Valuation : Waverley Pharma Inc.

Market Cap 810K 583K 502K 471K 430K 55.72M 813K 5.59M 2.18M 28.13M 2.19M 2.14M 93.26M P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 4.21M 3.03M 2.61M 2.45M 2.23M 290M 4.22M 29.04M 11.33M 146M 11.38M 11.13M 485M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
3 months+50.00%
Current year-25.00%
1 month 0.02
Extreme 0.015
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.12
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 2020-01-31
Director of Finance/CFO - 2019-12-31
Director TitleAgeSince
Chairman 79 2016-12-13
Director/Board Member 54 2016-12-13
Director/Board Member - 2023-11-21
Date Insider Type Main position Quantity % Market Cap.
8/16/26 Option

Chairman

-10,000,000 18.5185%
6/24/24 Other

Director

0 0%
8/18/21 Other

Chairman

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%0.00%-57.14% 583K
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -1.82%-1.73%+51.99%+166.65% 28.19B
Weighted average by Cap. -1.93%-1.50%+53.73%+151.51%

Financials

2024 2025
Net sales 475K 342K 295K 276K 252K 32.7M 477K 3.28M 1.28M 16.51M 1.28M 1.26M 54.73M 1.35M 971K 837K 785K 716K 92.84M 1.35M 9.31M 3.63M 46.86M 3.65M 3.57M 155M
Net income -947K -682K -587K -551K -503K -65.15M -950K -6.53M -2.55M -32.89M -2.56M -2.5M -109M -499K -359K -310K -290K -265K -34.34M -501K -3.44M -1.34M -17.33M -1.35M -1.32M -57.48M
Net Debt 2.83M 2.04M 1.76M 1.65M 1.5M 195M 2.84M 19.53M 7.62M 98.29M 7.65M 7.48M 326M 3.4M 2.45M 2.11M 1.98M 1.8M 234M 3.41M 23.45M 9.15M 118M 9.19M 8.99M 391M
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
26-08-27 CA$0.000000 -100.00% 650
  1. Stock Market
  2. Stocks
  3. WAVE Stock